Axon Neuroscience’s immunotherapy selected for a landmark combination-therapy Alzheimer’s clinical trial in US, supported by a USD 151 million grant
Axon Neuroscience’s active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer’s disease phase 2 clinical trial (supported by a USD 151…